RETRACTED ARTICLE: Probiotic assisted weight management as a main factor for glycemic control in patients with type 2 diabetes: a randomized controlled trial

Khalili, Leila; Alipour, Beitullah; Jafarabadi, Mohammad Asghari; Hassanalilou, Tohid; Abbasi, Mehran Mesgari; Faraji, Ismail

doi:10.1186/s13098-019-0400-7

Cited by 48 publications

(34 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Silymarin has a structure called silibinin which can protect the liver [6]. Silymarin has been reported as an effective compound in patients with type 2diabetes [7]., such as lack of useful medication and side effects in most of cases [8,9]. Zebra fish has been established as a suitable model among vertebrate for biomedical research with more than 85% genetic similarity to humans [10].…”

Section: Introductionmentioning

confidence: 99%

Concurrent metformin and silibinin therapy in diabetes: assessments in zebrafish (Danio rerio) animal model

Mohammadi

Manouchehri

Changizi

et al. 2020

J Diabetes Metab Disord

View full text Add to dashboard Cite

Objective In this study, zebrafish was used as a biological model to induce type 2 diabetes mellitus through glucose. Then, the effect of metformin and silibinin combination was examined on elevated blood glucose, intestinal tissues, liver enzymes, and TNF-α, IFN-γ, INL1β genes as inflammation marker genes. Methods The liver enzymes (AST, ALT, and ALP) derived from fish viscera homogenate supernatants were assayed in an auto-analyzer. The expression of target genes was quantified on RNA extracted from the tails by an in-house RT-PCR method, with fine intestine tissue staining performed by hematoxylin and eosin protocol (H&E). Result In the glucose-free treatments, metformin and silymarin decreased the levels of AST, ALT, and ALP enzymes in the blood. The combination of these two drugs had also a significant role in reducing glucose levels. The body weight increased significantly in the control group which was affected by glucose concentration, with the lowest body weight gain observed in the metformin group. The expression of INL-1β gene was significantly enhanced in the control group and the highest IFN-γ expression was observed in both control groups with glucose (G + CTRL) and without glucose (G-CTRL) (p < 0.05). The lowest level of TNF-α gene expression was observed in the control + glucose group (G + CTRL) (p < 0.05). Diabetic state causes weak absorption whereby the fish body demands to increase absorption level by enhancing the amount of acidic goblet cells thereby acidifying the environment in the gastric tracts. Conclusion Collectively, this study indicated that treatment with metformin and Silibinin could improve metabolic-mediated performances by reducing the expression of inflammatory genes and blood glucose, modulating liver enzymes, and ameliorating the intestinal inflammation in type 2 diabetic zebrafish model.

show abstract

Section: Introductionmentioning

confidence: 99%

Concurrent metformin and silibinin therapy in diabetes: assessments in zebrafish (Danio rerio) animal model

Mohammadi

Manouchehri

Changizi

et al. 2020

J Diabetes Metab Disord

View full text Add to dashboard Cite

show abstract

“…In addition to the bactericidal effect, the high colony number of Bifidobacteria after consuming LcS promotes fermentation in the intestine, decreases food intake and fat mass, and improves insulin secretion which ultimately helps to reduce weight gain 28 . Oral administration of probiotic facilitates thermogenic and lipolytic effects through stimulating the sympathetic nervous system, which leads to weight reduction 31 . On the other hand, the LC group in our study tended toward BMIZ reduction in female adolescents compared to the RC.…”

Section: Discussionmentioning

confidence: 99%

Tenth year reenrollment randomized trial investigating the effects of childhood probiotics and calcium supplementation on height and weight at adolescence

Setiawan

Rianda

Kadim

et al. 2021

Sci Rep

View full text Add to dashboard Cite

Microbiota and its modification with specific probiotics in early life could provide long term health benefits. Probiotics and calcium strengthen intestinal integrity and may support linear growth. This study investigated the long-term effects of childhood probiotics and calcium supplementation on growth in adolescence. We re-enrolled 238 adolescents aged 11–18 years from 494 children 10-years after 6-months of supplementation with either low-lactose milk fortified with low levels of calcium (LC, ∼50 mg/day, n = 53/124), with regular levels of calcium (RC, ∼440 mg/day, n = 70/126), or with regular calcium + 5 x 108 CFU/day Lactobacillus reuteri DSM 17938 (Reuteri, n = 55/124), or regular calcium + 5 x 108 CFU/day L. casei CRL 431 (Casei, n = 60/120). Changes in height-for-age z-score (HAZ) and body mass index-for-age z-score (BMIZ) were determined from the end of intervention to re-enrollment. General linear models were used to assess the effects on HAZ and BMIZ of group, gender, living area, maternal education, family income, physical activity, diet quality, nutritional status, and gut integrity as determined by urinary lactulose/mannitol ratio (L:M). Adolescent mean age was 15.3 years, mean HAZ was − 1.11, mean BMIZ was − 0.2 and median L:M (n = 155) was 0.23. Changes in HAZ and BMIZ were not significantly different between Casei, Reuteri, LC compared to RC. However, a significant decrease in BMIZ was observed among female adolescents in the Casei compared to RC group (− 0.5 SD, 95% CI − 0.8 to − 0.003, p = 0.048). Childhood probiotic and calcium supplementation may therefore selectively affect female adolescents.Clinical trial registration: This follow-up study has been registered at www.clinicaltrials.gov, Registry name: Rina Agustina, Registration number: NCT04046289, First Registration Date 06/08/19. web link: https://www.clinicaltrials.gov/ct2/show/NCT04046289.

show abstract

“…casei is a transient bacterium in the human body and can relieve hypocholesterolemia, atherosclerosis, and hypertension in mice/rats through a cholesterol-lowering mechanism attributed to the improvement of BAs, SCFAs, and TMAO (10,(101)(102)(103). L. casei 01 supplementation significantly decreased dietary intake and body weight through improving serum fetuin-A and sirtuin1 levels and glycemic response in T2DM patients (26). L. casei can also effectively treat T2DM and hyperglycemia by suppressing GM-mediated inflammation (104)(105)(106).…”

Section: Lactobacillus Caseimentioning

confidence: 99%

Therapeutic and Improving Function of Lactobacilli in the Prevention and Treatment of Cardiovascular-Related Diseases: A Novel Perspective From Gut Microbiota

et al. 2021

View full text Add to dashboard Cite

The occurrence and development of cardiovascular-related diseases are associated with structural and functional changes in gut microbiota (GM). The accumulation of beneficial gut commensals contributes to the improvement of cardiovascular-related diseases. The cardiovascular-related diseases that can be relieved by Lactobacillus supplementation, including hypercholesterolemia, atherosclerosis, myocardial infarction, heart failure, type 2 diabetes mellitus, and obesity, have expanded. As probiotics, lactobacilli occupy a substantial part of the GM and play important functional roles through various GM-derived metabolites. Lactobacilli ultimately have a beneficial impact on lipid metabolism, inflammatory factors, and oxidative stress to relieve the symptoms of cardiovascular-related diseases. However, the axis and cellular process of gut commensal Lactobacillus in improving cardiovascular-related diseases have not been fully elucidated. Additionally, Lactobacillus strains produce diverse antimicrobial peptides, which help maintain intestinal homeostasis and ameliorate cardiovascular-related diseases. These strains are a field that needs to be further investigated immediately. Thus, this review demonstrated the mechanisms and summarized the evidence of the benefit of Lactobacillus strain supplementation from animal studies and human clinical trials. We also highlighted a broad range of lactobacilli candidates with therapeutic capability by mining their metabolites. Our study provides instruction in the development of lactobacilli as a functional food to improve cardiovascular-related diseases.

show abstract

RETRACTED ARTICLE: Probiotic assisted weight management as a main factor for glycemic control in patients with type 2 diabetes: a randomized controlled trial

Cited by 48 publications

References 39 publications

Concurrent metformin and silibinin therapy in diabetes: assessments in zebrafish (Danio rerio) animal model

Concurrent metformin and silibinin therapy in diabetes: assessments in zebrafish (Danio rerio) animal model

Tenth year reenrollment randomized trial investigating the effects of childhood probiotics and calcium supplementation on height and weight at adolescence

Therapeutic and Improving Function of Lactobacilli in the Prevention and Treatment of Cardiovascular-Related Diseases: A Novel Perspective From Gut Microbiota

Contact Info

Product

Resources

About